scholarly journals Correction: IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery

RSC Advances ◽  
2016 ◽  
Vol 6 (66) ◽  
pp. 61267-61267 ◽  
Author(s):  
Shan Qian ◽  
Man Zhang ◽  
Quanlong Chen ◽  
Yanying He ◽  
Wei Wang ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Drug Target ◽  
Recent Developments ◽  
Ido Inhibitors

Correction for ‘IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery’ by Shan Qian et al., RSC Adv., 2016, 6, 7575–7581.

IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery

RSC Advances ◽  
2016 ◽  
Vol 6 (9) ◽  
pp. 7575-7581 ◽  
Author(s):  
Shan Qian ◽  
Man Zhang ◽  
Quanlong Chen ◽  
Yanying He ◽  
Wei Wang ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Small Molecule ◽  
Drug Target ◽  
Immune Escape ◽  
Chemical Structures ◽  
Modes Of Action ◽  
Recent Advances ◽  
Recent Developments ◽  
Ido Inhibitors

This review highlights the recent advances in research related to the role of IDO in immune escape in cancer and novel small-molecule IDO inhibitors with an emphasis on their chemical structures and modes of action.

Drug Target Identification in Tissues by Thermal Proteome Profiling

2021 ◽  
Vol 62 (1) ◽  
Author(s):  
André Mateus ◽  
Nils Kurzawa ◽  
Jessica Perrin ◽  
Giovanna Bergamini ◽  
Mikhail M. Savitski
Keyword(s):  
Drug Target ◽  
Target Identification ◽  
Annual Review ◽  
Publication Date ◽  
Proteome Profiling ◽  
Biological Phenomena ◽  
Target Deconvolution ◽  
Drug Target Identification ◽  
Recent Developments ◽  
Fundamental Biology

Drug target deconvolution can accelerate the drug discovery process by identifying a drug's targets (facilitating medicinal chemistry efforts) and off-targets (anticipating toxicity effects or adverse drug reactions). Multiple mass spectrometry–based approaches have been developed for this purpose, but thermal proteome profiling (TPP) remains to date the only one that does not require compound modification and can be used to identify intracellular targets in living cells. TPP is based on the principle that the thermal stability of a protein can be affected by its interactions. Recent developments of this approach have expanded its applications beyond drugs and cell cultures to studying protein-drug interactions and biological phenomena in tissues. These developments open up the possibility of studying drug treatment or mechanisms of disease in a holistic fashion, which can result in the design of better drugs and lead to a better understanding of fundamental biology. Expected final online publication date for the Annual Review of Pharmacology and Toxicology, Volume 62 is January 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

Immunoadjuvants for cancer immunotherapy: A review of recent developments

2020 ◽  
Vol 114 ◽  
pp. 16-30 ◽  
Author(s):  
Asmita Banstola ◽  
Jee-Heon Jeong ◽  
Simmyung Yook
Keyword(s):  
Cancer Immunotherapy ◽  
Recent Developments

scholarly journals Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy—Current Status and Future Perspectives

Vaccines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 935
Author(s):  
Ramar Thangam ◽  
Kapil D. Patel ◽  
Heemin Kang ◽  
Ramasamy Paulmurugan
Keyword(s):  
Cancer Immunotherapy ◽  
Anticancer Agents ◽  
Polymeric Nanoparticles ◽  
Current Status ◽  
Polymeric Nanocarriers ◽  
Therapeutic Drugs ◽  
Small Molecule Ligands ◽  
Recent Developments ◽  
Cancer Immunotherapies

Engineering polymeric nanoparticles for their shape, size, surface chemistry, and functionalization using various targeting molecules has shown improved biomedical applications for nanoparticles. Polymeric nanoparticles have created tremendous therapeutic platforms, particularly applications related to chemo- and immunotherapies in cancer. Recently advancements in immunotherapies have broadened this field in immunology and biomedical engineering, where “immunoengineering” creates solutions to target translational science. In this regard, the nanoengineering field has offered the various techniques necessary to manufacture and assemble multifunctional polymeric nanomaterial systems. These include nanoparticles functionalized using antibodies, small molecule ligands, targeted peptides, proteins, and other novel agents that trigger and encourage biological systems to accept the engineered materials as immune enhancers or as vaccines to elevate therapeutic functions. Strategies to engineer polymeric nanoparticles with therapeutic and targeting molecules can provide solutions for developing immune vaccines via maintaining the receptor storage in T- and B cells. Furthermore, cancer immunotherapy using polymeric nanomaterials can serve as a gold standard approach for treating primary and metastasized tumors. The current status of the limited availability of immuno-therapeutic drugs highlights the importance of polymeric nanomaterial platforms to improve the outcomes via delivering anticancer agents at localized sites, thereby enhancing the host immune response in cancer therapy. This review mainly focuses on the potential scientific enhancements and recent developments in cancer immunotherapies by explicitly discussing the role of polymeric nanocarriers as nano-vaccines. We also briefly discuss the role of multifunctional nanomaterials for their therapeutic impacts on translational clinical applications.

scholarly journals Anti-Cancer Immunotherapies Targeting Telomerase

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2260
Author(s):  
Simone Negrini ◽  
Raffaele De Palma ◽  
Gilberto Filaci
Keyword(s):  
Cancer Cells ◽  
Cancer Immunotherapy ◽  
Human Leukocyte ◽  
Clinical Settings ◽  
Leukocyte Antigen ◽  
Tumor Associated Antigen ◽  
Anti Cancer ◽  
Recent Developments ◽  
Human Telomerase ◽  
Cancer Immunotherapies

Telomerase is a reverse transcriptase that maintains telomeres length, compensating for the attrition of chromosomal ends that occurs during each replication cycle. Telomerase is expressed in germ cells and stem cells, whereas it is virtually undetectable in adult somatic cells. On the other hand, telomerase is broadly expressed in the majority of human tumors playing a crucial role in the replicative behavior and immortality of cancer cells. Several studies have demonstrated that telomerase-derived peptides are able to bind to HLA (human leukocyte antigen) class I and class II molecules and effectively activate both CD8+ and CD4+ T cells subsets. Due to its broad and selective expression in cancer cells and its significant immunogenicity, telomerase is considered an ideal universal tumor-associated antigen, and consequently, a very attractive target for anti-cancer immunotherapy. To date, different telomerase targeting immunotherapies have been studied in pre-clinical and clinical settings, these approaches include peptide vaccination and cell-based vaccination. The objective of this review paper is to discuss the role of human telomerase in cancer immunotherapy analyzing recent developments and future perspectives in this field.

Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy

Biomaterials ◽  
2021 ◽  
pp. 121018
Author(s):  
Yixuan Guo ◽  
Yu Liu ◽  
Wei Wu ◽  
Daishun Ling ◽  
Qiao Zhang ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Indoleamine 2,3 Dioxygenase ◽  
Ido Inhibitors

Recent developments in renal cell cancer immunotherapy

2007 ◽  
Vol 7 (5) ◽  
pp. 727-737 ◽  
Author(s):  
P J Wysocki ◽  
J Zolnierek ◽  
C Szczylik ◽  
A Mackiewicz
Keyword(s):  
Cancer Immunotherapy ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Recent Developments

Recent developments of RNA-based vaccines in cancer immunotherapy

2020 ◽  
pp. 1-18
Author(s):  
Elnaz Faghfuri ◽  
Farhad Pourfarzi ◽  
Amir Hossein Faghfouri ◽  
Mahdi Abdoli Shadbad ◽  
Khalil Hajiasgharzadeh ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Recent Developments
Sign in / Sign up

Export Citation Format

Share Document